Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.8%

4 terminated out of 37 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

11%

4 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed with results

Key Signals

2 with results80% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (7)
Early P 1 (1)
P 1 (6)
P 2 (12)
P 3 (4)

Trial Status

Completed16
Unknown7
Recruiting5
Terminated4
Not Yet Recruiting2
Withdrawn2

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT05579639Phase 2RecruitingPrimary

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT03286530Phase 2Active Not Recruiting

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

NCT06297629Phase 2WithdrawnPrimary

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06028828Phase 2Recruiting

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

NCT06926595Phase 2Not Yet Recruiting

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

NCT01166009Recruiting

CIBMTR Research Database

NCT06453460Phase 2Recruiting

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

NCT05447663Phase 1Terminated

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

NCT04628338Early Phase 1Completed

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06093334Not ApplicableCompleted

Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD

NCT05982275Phase 1Not Yet Recruiting

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

NCT06256341CompletedPrimary

HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.

NCT01092026Not ApplicableCompletedPrimary

Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells

NCT03882203Phase 2Completed

CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

NCT04920474Recruiting

Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

NCT03233659CompletedPrimary

Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation

NCT05088941CompletedPrimary

Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience

NCT05443854Phase 3Unknown

Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)

NCT03820908Phase 2Completed

Bisantrene for Relapsed /Refractory AML

NCT01374399Not ApplicableCompletedPrimary

Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA)

Scroll to load more

Research Network

Activity Timeline